Bracco Delivers 3 Million VUEWAY® Doses, Meeting Patient Demand for Lower-Dose MRI Contrast

PRINCETON, NJ – Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging, announced today that more than three million doses¹ of its magnetic resonance imaging (MRI) agent, VUEWAY^® (gadopiclenol) solution for injection, intravenous use, have been administered across 902 customer sites.² This milestone, since the U.S. Food and Drug Administration (FDA) approval of VUEWAY^® injection, reflects both strong market adoption and growing patient preference for lower-dose contrast agents. 

VUEWAY^® injection, a macrocyclic gadolinium-based contrast agent (GBCA), offers effective contrast enhancement at half the gadolinium (Gd) dose (0.05 mmol/kg) compared to other macrocyclic GBCAs for approved indications in the U.S.^3,4,5 (0.1 mmol/kg), helping to reduce cumulative Gd exposure in patients without compromising image quality. With contrast-enhanced MRI playing a critical role in detecting and monitoring conditions such as breast cancer and multiple sclerosis, VUEWAY^® injection is reshaping clinical practice by enabling patient-first innovation. VUEWAY^® solution for injection is administered globally in the United States and most European Union countries. 

"Innovation should always start with the patient, and the rapid adoption of VUEWAY^® injection shows that the industry agrees," said Noelle Heber, Executive Director, Radiology Platform, Bracco Diagnostics Inc. "This milestone of three million doses highlights the power of combining safety, efficacy, and patient preference in a single solution. We are grateful to the imaging community for their trust. Together, we are advancing patient-first care."

Survey Shows Demand for Lower-Dose Contrast 

A nationally representative survey commissioned by Bracco Diagnostics6 targeting 300 recipients of MRI scans with contrast found overwhelming support for lower-dose gadolinium contrast agents^*: 

• 92% were interested in an agent with half the gadolinium dose^*6
• 92% said they would likely request it for the procedure^†6
• 91% would consider switching MRI providers to access it^†6
• 90% were willing to travel at least 25 miles for a lower-dose option^‡6
• Among patients with multiple sclerosis, 78% preferred half dose Gd for repeated scans⁶
• Among those undergoing routine breast cancer screening, 85% expressed a strong interest in a half-dose option⁶ 

Conducted via a web-based platform, the survey included only contrast MRI recipients from the past 12 months and included high-frequency users, including those with chronic conditions or undergoing routine screening. The survey aimed to assess patient preferences, demand for reduced gadolinium dosage with equivalent image quality, demand for a very stable agent, and willingness to act.⁶ 

These findings underscore a growing awareness among patients around MRI contrast agent safety and their willingness to take an active role in their care decisions.⁶ 

Safety Profile Backed by Real-World Data

In its first year of clinical use (February 2023-March 2024), a post-marketing safety study of VUEWAY^® injection (gadopiclenol) in the United States evaluated 882,550 administrations using real-world data collected through pharmacovigilance databases of companies selling gadopiclenol.⁷ These systems continuously monitor the safety of every product the companies market globally and aggregate data from all available sources, including spontaneous reports, scientific literature, social media, regulatory agency databases, clinical and epidemiological studies, and administrative claims data from health insurers.⁷ 

Adverse events (AEs) were classified as "serious" or "non-serious" by qualified pharmacovigilance personnel, in accordance with international regulatory definitions. All reported symptoms were coded using the internationally recognized Medical Dictionary for Regulatory Activities (MedDRA) system.⁷ 

The study observed:⁷ 

• Zero serious adverse events
• Only 32 patients experienced adverse events 

Reporting rates were calculated by comparing the number of patients experiencing AEs to the number of gadopiclenol units sold in the U.S.—the only market where the product was available during the study period.⁷ 

This rigorous, real-world data reinforces the favorable safety profile of VUEWAY^® injection and highlights Bracco’s continued commitment to patient safety and innovation in diagnostic imaging.⁷ 

Todd Mulderink, MD, Chairman of the Department of Radiology at Corewell Health Grand Rapids, said, "The availability of a [high-relaxivity] contrast agent that lowers gadolinium exposure without sacrificing imaging quality is a game-changer and a win for both patients and radiologists charged with their MR imaging care."

With its unique combination of clinical efficacy, reduced gadolinium exposure, and strong patient support, VUEWAY^® injection is emerging as the new standard and a highly desirable choice for patients who require multiple contrast MRI exams over time. 

Bracco will continue to invest in innovation, real-world research, and education to empower radiologists and patients alike in making safer, informed choices in imaging. Beyond VUEWAY^® injection, Bracco continues to deliver innovation across its portfolio to support clinicians with the science, service, and breadth of solutions they need to advance care.